{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T09:27:34Z","timestamp":1786440454789,"version":"build-2736575974"},"reference-count":29,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"George Emil Palade University of Medicine, Pharmacy, Science, and Technology of T\u00e2rgu Mure\u0219","award":["171\/9\/09.01.2024"],"award-info":[{"award-number":["171\/9\/09.01.2024"]}]},{"award":["171\/9\/09.01.2024"],"award-info":[{"award-number":["171\/9\/09.01.2024"]}],"id":[{"id":"https:\/\/ror.org\/03gwbzf29","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Circulating extracellular vesicle-associated microRNAs (EV-miRNAs) are emerging as promising peripheral biomarkers in multiple sclerosis (MS). This prospective, observational pilot study was conceived as a hypothesis-generating investigation to characterize the expression profile of four candidate EV-miRNAs (miR-223-5p, miR-155-5p, miR-30a-5p, and miR-146a-5p) within an EV-enriched plasma fraction. The cohort comprised 16 patients with secondary progressive MS (SPMS) undergoing siponimod therapy, 13 age- and sex-matched healthy controls (HCs), and 7 patients with relapsing\u2013remitting MS (RRMS) included as an exploratory comparator. Quantification was performed by quantitative real-time PCR employing the \u0394\u0394C_t methodology, with miR-16-5p as the endogenous normalizer. Analyses were conducted cross-sectionally and longitudinally, the latter within a paired subgroup of 11 SPMS patients evaluated at baseline and after twelve months of uninterrupted treatment. Cross-sectional comparisons demonstrated a significant downregulation of EV-miR-223-5p in SPMS patients relative to HCs (fold-change [FC] = 0.26; FDR q = 0.026), whereas EV-miR-155-5p was significantly reduced in both the SPMS (FC = 0.35; FDR q = 0.033) and RRMS (FC = 0.28; FDR q = 0.046) cohorts compared with HCs. No significant intergroup differences were observed for EV-miR-30a-5p or EV-miR-146a-5p. Longitudinal assessment revealed no significant modulation of any target EV-miRNA following one year of siponimod therapy. These preliminary observations should be interpreted with caution, given the exploratory nature and modest cohort size. Importantly, the isolation of total plasma EVs does not permit resolution of the specific cellular provenance of the observed signals, nor does it capture their downstream functional consequences. Nevertheless, the selective downregulation of EV-miR-223-5p and EV-miR-155-5p may tentatively suggest candidate molecular signatures warranting further interrogation. Adequately powered studies incorporating cell-specific EV sorting and paired cerebrospinal fluid sampling will be required to substantiate these signals and clarify their potential utility in monitoring disease progression and therapeutic response in progressive MS.<\/jats:p>","DOI":"10.3390\/cells15161441","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T08:09:36Z","timestamp":1786435776000},"page":"1441","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Extracellular Vesicle-Associated miRNA in Multiple Sclerosis Subtypes: Differential Profiles in Secondary Progressive Disease and the Effect of One-Year Siponimod Treatment"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5518-5864","authenticated-orcid":false,"given":"Oana","family":"Vr\u00eenceanu","sequence":"first","affiliation":[{"name":"Doctoral School, \u201cGeorge Emil Palade\u201d University of Medicine, Pharmacy, Science, and Technology of Targu Mures, 540142 Targu Mures, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Smaranda","family":"Maier","sequence":"additional","affiliation":[{"name":"Department of Neurology, \u201cGeorge Emil Palade\u201d University of Medicine, Pharmacy, Science, and Technology of Targu Mures, 540136 Targu Mures, Romania"},{"name":"1st Neurology Clinical, Emergency Clinical County Hospital Targu Mures, 540136 Targu Mures, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doina","family":"Manu","sequence":"additional","affiliation":[{"name":"Center for Advanced Medical and Pharmaceutical Research, \u201cGeorge Emil Palade\u201d University of Medicine, Pharmacy, Science, and Technology of Targu Mures, 540142 Targu Mures, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3235-524X","authenticated-orcid":false,"given":"Claudia","family":"B\u0103nescu","sequence":"additional","affiliation":[{"name":"Center for Advanced Medical and Pharmaceutical Research, \u201cGeorge Emil Palade\u201d University of Medicine, Pharmacy, Science, and Technology of Targu Mures, 540142 Targu Mures, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodica","family":"B\u0103la\u0219a","sequence":"additional","affiliation":[{"name":"Doctoral School, \u201cGeorge Emil Palade\u201d University of Medicine, Pharmacy, Science, and Technology of Targu Mures, 540142 Targu Mures, Romania"},{"name":"Department of Neurology, \u201cGeorge Emil Palade\u201d University of Medicine, Pharmacy, Science, and Technology of Targu Mures, 540136 Targu Mures, Romania"},{"name":"1st Neurology Clinical, Emergency Clinical County Hospital Targu Mures, 540136 Targu Mures, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/s41392-025-02415-4","article-title":"Multiple sclerosis: Molecular pathogenesis and therapeutic intervention","volume":"10","author":"Eixarch","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"110608","DOI":"10.1016\/j.clim.2025.110608","article-title":"Cerebrospinal fluid exosomal Epstein-Barr virus microRNAs in multiple sclerosis and effects of disease modifying therapies","volume":"281","author":"Hvalkof","year":"2025","journal-title":"Clin. Immunol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Balasa, R., Barcutean, L., Mosora, O., and Manu, D. (2021). Reviewing the Significance of Blood-Brain Barrier Disruption in Multiple Sclerosis Pathology and Treatment. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22168370"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s40263-022-00927-z","article-title":"The Two Sides of Siponimod: Evidence for Brain and Immune Mechanisms in Multiple Sclerosis","volume":"36","author":"Cohan","year":"2022","journal-title":"CNS Drugs"},{"key":"ref_5","unstructured":"(2026, July 13). Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/mayzent."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Kr\u00e5kenes, T., Sandvik, C.E., Ytterdal, M., Gavasso, S., Evjenth, E.C., B\u00f8, L., and Kvistad, C.E. (2024). The Therapeutic Potential of Exosomes from Mesenchymal Stem Cells in Multiple Sclerosis. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms251910292"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"14293","DOI":"10.1038\/s41598-017-14301-3","article-title":"Exosomal microRNA signatures in multiple sclerosis reflect disease status","volume":"7","author":"Ebrahimkhani","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12974-024-03019-5","article-title":"Microglia-derived exosomes modulate myelin regeneration via miR-615-5p\/MYRF axis","volume":"21","author":"Ji","year":"2024","journal-title":"J. Neuroinflamm."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Lin, B., Jiang, J., Jia, J., and Zhou, X. (2022). Recent Advances in Exosomal miRNA Biosensing for Liquid Biopsy. Molecules, 27.","DOI":"10.3390\/molecules27217145"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Zabalza, A., Pappolla, A., Comabella, M., Montalban, X., and Malhotra, S. (2024). MiRNA-based therapeutic potential in multiple sclerosis. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1441733"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1179069518764892","DOI":"10.1177\/1179069518764892","article-title":"The Role for Exosomal microRNAs in Disruption of Regulatory T Cell Homeostasis in Multiple Sclerosis","volume":"12","author":"Kimura","year":"2018","journal-title":"J. Exp. Neurosci."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e12404","DOI":"10.1002\/jev2.12404","article-title":"Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches","volume":"13","author":"Welsh","year":"2024","journal-title":"J. Extracell. Vesicles"},{"key":"ref_13","unstructured":"(2026, July 13). Available online: https:\/\/www.systembio.com\/products\/exosome-research\/exosome-isolation\/exoquick-ultra\/serum-and-plasma-0\/the-purest-and-highest-yielding-ev-isolation-system."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e12260","DOI":"10.1002\/jev2.12260","article-title":"Understanding the extracellular vesicle surface for clinical molecular biology","volume":"11","author":"Hallal","year":"2022","journal-title":"J. Extracell. Vesicles"},{"key":"ref_15","unstructured":"(2026, July 13). Available online: https:\/\/documents.thermofisher.com\/TFS-Assets\/LSG\/manuals\/cms_055423.pdf."},{"key":"ref_16","unstructured":"(2026, July 13). Available online: https:\/\/documents.thermofisher.com\/TFS-Assets\/LSG\/manuals\/4364031_TaqSmallRNA_UG.pdf."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.7150\/ijbs.59876","article-title":"miR-223: An Effective Regulator of Immune Cell Differentiation and Inflammation","volume":"17","author":"Jiao","year":"2021","journal-title":"Int. J. Biol. Sci."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/jnc.15650","article-title":"Investigating the NLRP3 inflammasome and its regulator miR-223-3p in multiple sclerosis and experimental demyelination","volume":"163","author":"Galloway","year":"2022","journal-title":"J. Neurochem."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"5208","DOI":"10.1038\/s41598-026-35189-y","article-title":"Extracellular vesicle-derived miR-760 as a novel promising candidate biomarker differentiating stable RRMS from SPMS","volume":"16","author":"Wasilewska","year":"2026","journal-title":"Sci. Rep."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Mosora, O., Maier, S., Manu, D., B\u0103rcu\u021bean, L., Roman, M., Dumitreas\u0103, M., and B\u0103la\u0219a, R. (2025). Exosomal microRNAs as Early Transition Biomarkers from Recurrent-Remissive to Secondary Progressive Multiple Sclerosis. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26083889"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1096\/fj.13-248880","article-title":"MicroRNA-155 negatively affects blood-brain barrier function during neuroinflammation","volume":"28","author":"Wu","year":"2014","journal-title":"FASEB J."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Maciak, K., Dziedzic, A., Miller, E., and Saluk-Bijak, J. (2021). miR-155 as an Important Regulator of Multiple Sclerosis Pathogenesis. A Review. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22094332"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1002\/ana.23967","article-title":"miR-155 as a multiple sclerosis-relevant regulator of myeloid cell polarization","volume":"74","author":"Moore","year":"2013","journal-title":"Ann. Neurol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Ali Ashrafi, S., Asadi, M., Shanehbandi, D., Sadigh Eteghad, S., Fazlollahi, A., Nejadghaderi, S.A., and Shaafi, S. (2022). Association between miRNA-145 and miRNA-155 expression in peripheral blood mononuclear cells of patients with multiple sclerosis: A case-control study. BMC Neurol., 22.","DOI":"10.1186\/s12883-022-02909-6"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Wang, L., and Liang, Y. (2022). MicroRNAs as T Lymphocyte Regulators in Multiple Sclerosis. Front. Mol. Neurosci., 15.","DOI":"10.3389\/fnmol.2022.865529"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e32685","DOI":"10.1016\/j.heliyon.2024.e32685","article-title":"miR-24-3p and miR-484 are potential biomarkers for neurodegeneration in multiple sclerosis","volume":"10","author":"Alroughani","year":"2024","journal-title":"Heliyon"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Gurrea-Rubio, M., Wang, Q., Mills, E.A., Wu, Q., Pitt, D., Tsou, P.S., Fox, D.A., and Mao-Draayer, Y. (2024). Siponimod Attenuates Neuronal Cell Death Triggered by Neuroinflammation via NF\u03baB and Mitochondrial Pathways. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25052454"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Colombo, E., Bassani, C., De Angelis, A., Ruffini, F., Ottoboni, L., Comi, G., Martino, G., and Farina, C. (2020). Siponimod (BAF312) Activates Nrf2 While Hampering NF\u03baB in Human Astrocytes, and Protects From Astrocyte-Induced Neurodegeneration. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.00635"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s12974-023-02811-z","article-title":"miRNA 548a-3p as biomarker of NEDA-3 at 2 years in multiple sclerosis patients treated with fingolimod","volume":"20","author":"Patel","year":"2023","journal-title":"J. Neuroinflamm."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/15\/16\/1441\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T08:29:12Z","timestamp":1786436952000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/15\/16\/1441"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,11]]},"references-count":29,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["cells15161441"],"URL":"https:\/\/doi.org\/10.3390\/cells15161441","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,11]]}}}